Last reviewed · How we verify

NCT02310503: REGESMOHS

Spanish Registry of Mohs Surgery

Completed Last updated 5 May 2020
What this trial tests

trial testing Mohs surgery in Skin Neoplasms in 6,000 participants. Completed in 29 February 2020.

Timeline
1 July 2013
Primary endpoint
29 February 2020
29 February 2020

Quick facts

Lead sponsorFundación Academia Española de Dermatología
StatusCompleted
Study typeOBSERVATIONAL
Enrollment6,000
Start date1 July 2013
Primary completion29 February 2020
Estimated completion29 February 2020
Sites15 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Fundación Academia Española de Dermatología

Who can join

18 and older, female only, with Skin Neoplasms or Carcinoma, Basal Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

REGESMOHS (Registro Español de cirugía de Mohs) aims at describing effectiveness of Mohs surgery, and patient, tumor and technique factors related to adverse events and tumor recurrence. REGESMOHS is a prospective cohort, including all patients considered for Mohs surgery in participating centers. All consecutive patients are included. The only exclusion criteria are being under 18-years-old or legally incompetent. Pre-planned follow-up is as required by common clinical practice, but at least once a year for the study period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Skin Neoplasms

Currently open trials in the same condition.

Other Fundación Academia Española de Dermatología trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02310503.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing